Aida Pharmaceuticals Announces new Antibiotic Drug under Development
News Apr 10, 2008
Aida Pharmaceuticals, Inc. has announced that its recently-acquired research institute in the Jiangsu Province, the Jiangsu Institute of Microbiology Co., Ltd (JSIM) is developing a new wide-spectrum antibiotic, Wetimicin, in the People's Republic of China.
Wetimicin is from the newest generation of amino-glycoside family of antibiotics and is being tested for the treatment of various inflammations, such as respiratory infection, urinogenital infection, soft skin tissue infection as well as infections from trauma and operations.
The research for this new drug started in 2000 and it is currently undergoing Phase 1 clinical trials in conjunction with the Chinese government's State Food and Drug Administration ("SFDA").
The company believes that Phase 2 testing will commence some time in 2008. The company will have the right of first refusal of the manufacturing and marketing of the drug once it is approved by the SFDA as a Category A innovative new drug.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE